NCT00548093 is a Phase 2 clinical trial of PF-00299804 in Carcinoma, Non Small Cell Lung, sponsored by Pfizer.

Who is sponsoring NCT00548093?

NCT00548093 is sponsored by Pfizer.

What drugs are being tested in NCT00548093?

Interventions in NCT00548093: PF-00299804, PF-00299804.

What condition does NCT00548093 study?

NCT00548093 studies Carcinoma, Non Small Cell Lung.

Is NCT00548093 still recruiting?

NCT00548093 is currently completed. Last updated 21 May 2019.

Are results published for NCT00548093?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-05-21 · How we verify

NCT00548093

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Completed Phase 2 Results posted Last updated 21 May 2019

What this trial tests

Phase 2 trial testing PF-00299804 in Carcinoma, Non Small Cell Lung in 66 participants. Completed in 11 June 2012.

Timeline

29 April 2008

Primary endpoint
16 March 2010

11 June 2012

Quick facts

Lead sponsor	Pfizer
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Masking	none
Primary purpose	treatment
Enrollment	66
Start date	29 April 2008
Primary completion	16 March 2010
Estimated completion	11 June 2012
Sites	19 locations across United States

Drugs / interventions tested

PF-00299804 — full drug profile →
PF-00299804 — full drug profile →

Conditions studied

Carcinoma, Non Small Cell Lung — all drugs for Carcinoma, Non Small Cell Lung →

Sponsor

Pfizer — full company profile →

Who can join

Adults 18 to 99, any sex, with Carcinoma, Non Small Cell Lung. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Best Overall Response (BOR) in Participants With Adenocarcinoma Histology Primary · Baseline, end of every even-numbered cycle up to end of treatment (Day 936)

BOR:best response recorded from treatment start until disease progression as per Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response: disappearance of all lesions. Partial Response (PR):greater than or equal to (\>=)30% decrease in sum of longest diameters (SLDs) of target lesions (TLs) taking as reference baseline SLD. Progressive disease (PD):\>=20% increase in SLD of TLs taking as reference smallest SLD since treatment start, or appearance of \>=1 new lesion. Stable disease:neither shrinkage for PR nor increase for PD taking as reference smallest SLD since treatment sta

Complete response

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	0

Partial response

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	2

Stable or No response

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	28

Objective progression

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	12

Indeterminate

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	0

Best Overall Response (BOR) in Participants With Non-Adenocarcinoma Histology Secondary · Baseline, end of every even-numbered cycle up to end of treatment (Day 936)

BOR: best response recorded from treatment start until disease progression as per RECIST. Complete Response: disappearance of all lesions. PR: \>=30% decrease in SLDs of TLs taking as reference baseline SLD. PD: \>=20% increase in SLD of TLs taking as reference smallest SLD since treatment start, or appearance of \>=1 new lesion. Stable disease: neither shrinkage for PR nor increase for PD taking as reference smallest SLD since treatment start.

Complete response

Group	Value	95% CI
PF-00299804 (Non-adenocarcinoma Histology)	0

Partial response

Group	Value	95% CI
PF-00299804 (Non-adenocarcinoma Histology)	1

Stable or no response

Group	Value	95% CI
PF-00299804 (Non-adenocarcinoma Histology)	8

Objective progression

Group	Value	95% CI
PF-00299804 (Non-adenocarcinoma Histology)	7

Indeterminate

Group	Value	95% CI
PF-00299804 (Non-adenocarcinoma Histology)	0

Duration of Response (DR) Secondary · Baseline, end of every even-numbered cycle up to end of treatment (Day 936)

Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	45.2	24.1 – 66.3
PF-00299804 (Non-adenocarcinoma Histology)	12.1	NA – NA

Percent Probability of Progression-free Survival (PFS) at Month 6 Secondary · Up to 6 months after the start of study medication

Probability of being event free (event defined as PD or death due to any cause) at 6 months after the first dose of study treatment. PFS was defined as the time from the first dosing date to the date of first documentation of progression or death due to any cause, whichever occurs first. PFS was calculated as (first event date (if not reached, censored at the last known event-free date) minus first dosing date plus 1). Documentation of progression was determined from objective disease assessment based on RECIST v1.0 criteria. PD was defined as at least a 20% increase in the sum of the longest

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	24.3	12.4 – 38.4
PF-00299804 (Non-adenocarcinoma Histology)	8.0	0.5 – 29.8

Percent Probability of Overall Survival at Months 6 and 12 Secondary · Months 6, 12

Probability of being alive at 6 and 12 months after the first dose of study medication.

Month 6

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	71.5	56.7 – 82.1
PF-00299804 (Non-adenocarcinoma Histology)	50.0	24.5 – 71.0

Month 12

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	46.3	31.4 – 59.9
PF-00299804 (Non-adenocarcinoma Histology)	21.9	5.6 – 44.9

Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] Secondary · 0.5-2, 3-5, 6-8, 22-26 hours post dose on Day 1 of Cycle 1

The pharmacokinetic (PK) samples collected between 22-26 hours post dose on Day 1 of Cycle 1 were within the pre-specified time window for the 24-hour post dose sample and were used for calculation of AUC (0-24) on Day 1 of Cycle 1.

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	390.8	± 165.24
PF-00299804 (Non-adenocarcinoma Histology)	397.9	± 258.11

Maximum Observed Plasma Concentration (Cmax) Secondary · 0.5-2, 3-5, 6-8, 22-26 hours post dose on Day 1 of Cycle 1

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	22.61	± 10.315
PF-00299804 (Non-adenocarcinoma Histology)	25.49	± 22.533

Time to Reach Maximum Observed Plasma Concentration (Tmax) Secondary · 0.5-2, 3-5, 6-8, 22-26 hours post dose on Day 1 of Cycle 1

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	6.08	3.00 – 25.1
PF-00299804 (Non-adenocarcinoma Histology)	6.17	5.00 – 25.7

Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum Secondary · Baseline [pre-dose on Cycle 1 Day 1 (C1D1)], then pre-dose on Day 1 of each cycle, end of treatment (Day 936)

Human epidermal growth factor receptor 2 (HER2) is a transmembrane protein that plays a pivotal role in growth factor signal transduction and epidermal growth factor receptor (EGFR) is a cell surface protein that binds to epidermal growth factor. Levels of the HER-2 and EGFR extracellular domains in serum were assessed by enzyme-linked immunosorbent assay (ELISA).

EGFR: C1D1

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	51.25	± 14.86
PF-00299804 (Non-adenocarcinoma Histology)	57.28	± 15.36

EGFR: C2D1

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	45.89	± 12.42
PF-00299804 (Non-adenocarcinoma Histology)	51.05	± 11.35

EGFR: C3D1

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	44.91	± 11.43
PF-00299804 (Non-adenocarcinoma Histology)	46.79	± 7.64

EGFR: C4D1

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	46.26	± 11.7
PF-00299804 (Non-adenocarcinoma Histology)	46.72	± 9.01

EGFR: C5D1

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	45.35	± 11.32
PF-00299804 (Non-adenocarcinoma Histology)	51.2	± 9.76

EGFR: C6D1

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	48.71	± 12.01
PF-00299804 (Non-adenocarcinoma Histology)	66.52	± 20.19

EGFR: C7D1

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	52.85	± 15.6
PF-00299804 (Non-adenocarcinoma Histology)	44.29	± 9.55

EGFR: C8D1

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	50.27	± 17.05
PF-00299804 (Non-adenocarcinoma Histology)	55.93	± NA

Number of Participants With Human Epidermal Growth Factor Family (HER-Family) and Kirsten Rat Sarcoma (KRAS) Gene Mutation Status From Free Tumor Deoxy- Ribonucleic Acid (DNA) in Blood at Screening Secondary · Screening

HER-family is a family of transmembrane protein that plays a pivotal role in growth factor signal transduction and Kirsten Rat Sarcoma (KRAS) gene is an oncogene that encodes a small guanosine triphosphatase (GTPase) transductor protein called KRAS. The mutation status of HER and KRAS genes in tumor DNA present in plasma was determined using a polymerase chain reaction (PCR)-based assay. The gene that is most common in a particular natural population is known as the wild type. Any form of the gene other than the wild type is known as a mutant form. Number of participants with HER-Family and KR

KRAS mutation: Wild-type

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	39
PF-00299804 (Non-adenocarcinoma Histology)	15

KRAS mutation: Mutant

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	0
PF-00299804 (Non-adenocarcinoma Histology)	0

KRAS mutation: Unknown

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	11
PF-00299804 (Non-adenocarcinoma Histology)	1

HER-2 mutation: Wild-type

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	29
PF-00299804 (Non-adenocarcinoma Histology)	13

HER-2 mutation: Mutant

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	0
PF-00299804 (Non-adenocarcinoma Histology)	0

HER-2 mutation: Unknown

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	21
PF-00299804 (Non-adenocarcinoma Histology)	3

European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score Secondary · Baseline (C1D1), C2D1 thereafter every subsequent cycle up to C43

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status (GHS), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.

C1D1: GHS

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	65.83	± 24.99
PF-00299804 (Non-adenocarcinoma Histology)	60.56	± 25.87

C1D1: Physical functioning

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	74.70	± 22.17
PF-00299804 (Non-adenocarcinoma Histology)	70.22	± 27.24

C1D1: Role functioning

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	72.67	± 33.46
PF-00299804 (Non-adenocarcinoma Histology)	74.44	± 32.04

C1D1: Emotional Functioning

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	77.72	± 23.87
PF-00299804 (Non-adenocarcinoma Histology)	77.22	± 16.51

C1D1: Cognitive Functioning

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	81.33	± 24.89
PF-00299804 (Non-adenocarcinoma Histology)	76.67	± 28.73

C1D1: Social Functioning

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	76.33	± 30.69
PF-00299804 (Non-adenocarcinoma Histology)	67.78	± 26.33

C1D1: Fatigue

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	36.44	± 25.99
PF-00299804 (Non-adenocarcinoma Histology)	44.44	± 26.89

C1D1: Nausea, vomiting

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	10.33	± 18.10
PF-00299804 (Non-adenocarcinoma Histology)	10.00	± 17.59

European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score Secondary · Baseline (C1D1), C2D1 thereafter every subsequent cycle up to C43

QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnoea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.

C1D1: Dyspnoea

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	25.85	± 22.84
PF-00299804 (Non-adenocarcinoma Histology)	26.98	± 21.67

C1D1: Coughing

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	33.33	± 30.12
PF-00299804 (Non-adenocarcinoma Histology)	33.33	± 25.20

C1D1: Hemoptysis

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	2.00	± 10.45
PF-00299804 (Non-adenocarcinoma Histology)	4.44	± 11.73

C1D1: Sore mouth

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	3.33	± 10.10
PF-00299804 (Non-adenocarcinoma Histology)	6.67	± 18.69

C1D1: Dysphagia

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	2.67	± 9.13
PF-00299804 (Non-adenocarcinoma Histology)	0.00	± 0.00

C1D1: Peripheral neuropathy

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	10.00	± 18.13
PF-00299804 (Non-adenocarcinoma Histology)	13.33	± 24.56

C1D1: Alopecia

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	8.16	± 25.94
PF-00299804 (Non-adenocarcinoma Histology)	22.22	± 37.09

C1D1: Chest pain

Group	Value	95% CI
PF-00299804 (Adenocarcinoma Histology)	14.67	± 27.07
PF-00299804 (Non-adenocarcinoma Histology)	20.00	± 30.34

Adverse events — posted to ClinicalTrials.gov

Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

PF-00299804 (Adenocarcinoma Histology)

Serious: 9/50 (18%)

Deaths: —

PF-00299804 (Non-adenocarcinoma Histology)

Serious: 6/16 (38%)

Deaths: —

Serious adverse events (24 terms)

Reaction	System	PF-00299804 (Adenocarcinom…	PF-00299804 (Non-adenocarc…
Disease progression	General disorders	—	—
Respiratory failure	Respiratory, thoracic and mediastinal disorders	—	—
Abdominal pain	Gastrointestinal disorders	—	—
Constipation	Gastrointestinal disorders	—	—
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	—	—
Anaemia	Blood and lymphatic system disorders	—	—
Diarrhoea	Gastrointestinal disorders	—	—
Nausea	Gastrointestinal disorders	—	—
Pancreatitis	Gastrointestinal disorders	—	—
Vomiting	Gastrointestinal disorders	—	—
Asthenia	General disorders	—	—
Cystitis	Infections and infestations	—	—
Pneumonia	Infections and infestations	—	—
Hip fracture	Injury, poisoning and procedural complications	—	—
Spinal compression fracture	Injury, poisoning and procedural complications	—	—
Dehydration	Metabolism and nutrition disorders	—	—
Hypercalcaemia	Metabolism and nutrition disorders	—	—
Non-small cell lung cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—
Renal failure acute	Renal and urinary disorders	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—
Haemoptysis	Respiratory, thoracic and mediastinal disorders	—	—
Hypoxia	Respiratory, thoracic and mediastinal disorders	—	—
Pneumonia aspiration	Respiratory, thoracic and mediastinal disorders	—	—
Hypotension	Vascular disorders	—	—

Other adverse events (185 terms — click to expand)

Reaction	System	PF-00299804 (Adenocarcinom…	PF-00299804 (Non-adenocarc…
Diarrhoea	Gastrointestinal disorders	—	—
Dermatitis acneiform	Skin and subcutaneous tissue disorders	—	—
Fatigue	General disorders	—	—
Dry skin	Skin and subcutaneous tissue disorders	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—
Stomatitis	Gastrointestinal disorders	—	—
Nausea	Gastrointestinal disorders	—	—
Exfoliative rash	Skin and subcutaneous tissue disorders	—	—
Vomiting	Gastrointestinal disorders	—	—
Weight decreased	Investigations	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—
Upper respiratory tract infection	Infections and infestations	—	—
Aspartate aminotransferase increased	Investigations	—	—
Muscle spasms	Musculoskeletal and connective tissue disorders	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—
Skin fissures	Skin and subcutaneous tissue disorders	—	—
Cheilitis	Gastrointestinal disorders	—	—
Constipation	Gastrointestinal disorders	—	—
Paronychia	Infections and infestations	—	—
Hypoalbuminaemia	Metabolism and nutrition disorders	—	—
Hypomagnesaemia	Metabolism and nutrition disorders	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—
Erythema	Skin and subcutaneous tissue disorders	—	—
Nail disorder	Skin and subcutaneous tissue disorders	—	—
Abdominal pain	Gastrointestinal disorders	—	—
Chest pain	General disorders	—	—
Mucosal inflammation	General disorders	—	—
Oedema peripheral	General disorders	—	—
Urinary tract infection	Infections and infestations	—	—
Blood alkaline phosphatase increased	Investigations	—	—
Hypocalcaemia	Metabolism and nutrition disorders	—	—
Dysgeusia	Nervous system disorders	—	—
Epistaxis	Respiratory, thoracic and mediastinal disorders	—	—
Anaemia	Blood and lymphatic system disorders	—	—
Conjunctivitis	Eye disorders	—	—
Pain	General disorders	—	—
Alanine aminotransferase increased	Investigations	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—
Hypophosphataemia	Metabolism and nutrition disorders	—	—

Most-reported serious reactions: Disease progression, Respiratory failure, Abdominal pain, Constipation, Pulmonary embolism, Anaemia, Diarrhoea, Nausea.

Data from ClinicalTrials.gov NCT00548093 adverse events section.

Sponsor's own description

To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS, Kobayashi S, Costa DB. · · 2009 · cited 340× · PMID 19632948 · DOI 10.3816/clc.2009.n.039
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Jänne PA, Boss DS, Camidge DR, Britten CD, et al · · 2011 · cited 146× · PMID 21220471 · DOI 10.1158/1078-0432.ccr-10-1220
EGFR-mutated lung cancer: a paradigm of molecular oncology.
Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, et al · · 2010 · cited 136× · PMID 21165163 · DOI 10.18632/oncotarget.186
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Reckamp KL, Giaccone G, Camidge DR, Gadgeel SM, et al · · 2014 · cited 102× · PMID 24501009 · DOI 10.1002/cncr.28561
Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives.
Cheng X, Chen H. · · 2014 · cited 61× · PMID 25285017 · DOI 10.2147/ott.s66502
Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer.
Ivanova E, Kuraguchi M, Xu M, Portell AJ, et al · · 2020 · cited 38× · PMID 32034078 · DOI 10.1158/1078-0432.ccr-19-1844
Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
Lavacchi D, Mazzoni F, Giaccone G. · · 2019 · cited 35× · PMID 31564835 · DOI 10.2147/dddt.s194231
Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH, Soo RA. · · 2015 · cited 21× · PMID 26508839 · DOI 10.2147/dddt.s52787

Verify or expand the search:

Other trials of PF-00299804

Trials testing the same drug.

NCT01000025 — PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Meta · Phase 3 · completed
NCT00728390 — A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks · Phase 1 · completed
NCT00768664 — Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamou · Phase 2 · completed
NCT00553254 — Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer · Phase 2 · completed
NCT00225121 — Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumo · Phase 1 · completed

Other recruiting trials for Carcinoma, Non Small Cell Lung

Currently open trials in the same condition.

NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting
NCT06974734 — A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies · Phase 1 · active not recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00548093 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 21 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00548093.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing